Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacillus anthracis lethal factor (LF) is one of three components of the anthrax toxin secreted by Bacillus anthracis—the bacterium responsible for anthrax[1][3][6]. LF is an 85-kDa zinc-dependent metalloprotease enzyme that enters host cells via complex formation with another toxin component, protective antigen (PA)[1][2][3]. Once inside, LF specifically cleaves the N-terminus of mitogen-activated protein kinase kinases (MAPKKs), thereby inhibiting critical intracellular signaling pathways. This disruption leads to lethal cellular effects, particularly rapid death of macrophages through lysis or apoptosis, and ultimately contributes to multisystem organ failure in anthrax infection[1][2][4]. LF is a validated therapeutic target for toxin-neutralizing strategies, including small-molecule inhibitors or monoclonal antibodies (none currently approved for direct human therapy)[4][6].
Zinc metalloprotease activity: LF enters host cells with the help of protective antigen, then cleaves MAPKKs inside the cytoplasm, disrupting the MAPK signaling pathway and leading to immune cell apoptosis or lysis[1][3][4].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacillus anthracis lethal factor (LF).